Menu
Search
|

Menu

Close
X

Retrophin Inc RTRX.OQ (NASDAQ Stock Exchange Global Market)

12.18 USD
+0.45 (+3.84%)
As of Sep 13
Previous Close 11.73
Open 11.75
Volume 200,752
3m Avg Volume 172,871
Today’s High 12.30
Today’s Low 11.66
52 Week High 30.21
52 Week Low 11.39
Shares Outstanding (mil) 38.39
Market Capitalization (mil) 948.89
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.50 Mean rating from 8 analysts

KEY STATS

Revenue (mm, USD)
FY19
84
FY18
164
FY17
155
FY16
134
EPS (USD)
FY19
-1.912
FY18
-2.540
FY17
-1.504
FY16
-1.287
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.66
Price to Sales (TTM)
vs sector
6.60
7.91
Price to Book (MRQ)
vs sector
3.20
5.38
Price to Cash Flow (TTM)
vs sector
--
24.36
Total Debt to Equity (MRQ)
vs sector
15.13
14.55
LT Debt to Equity (MRQ)
vs sector
15.13
10.20
Return on Investment (TTM)
vs sector
-15.89
14.48
Return on Equity (TTM)
vs sector
-22.95
15.78

EXECUTIVE LEADERSHIP

Gary Lyons
Independent Chairman of the Board, Since 2016
Salary: --
Bonus: --
Eric Dube
President, Chief Executive Officer, Director, Since 2019
Salary: --
Bonus: --
Laura Clague
Chief Financial Officer, Senior Vice President, Since 2014
Salary: $399,583.00
Bonus: --
Elizabeth Reed
Senior Vice President, General Counsel and Corporate Secretary, Since 2017
Salary: $331,349.00
Bonus: --
William Rote
Senior Vice President and Head of Research and Development, Since 2017
Salary: $420,250.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

3721 Valley Centre Dr Ste 200
SAN DIEGO   CA   92130-3330

Phone: +1760.2608600

Retrophin, Inc. is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Chenodal has also been care for cerebrotendinous xanthomatosis (CTX) patients. Its Cholbam is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders. Its Thiola is approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria.

SPONSORED STORIES